Compare Bank of Nova Scotia (BNS) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Novavax Inc — how do they compare? Bank of Nova Scotia trades at $89.03 (market cap $108.32B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Bank of Nova Scotia is far larger — about 82.7× Novavax Inc's market cap, and Bank of Nova Scotia pays a 3.64% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| BNS | NVAX | |
|---|---|---|
Market Cap | $108.32B | $1.31B |
Sector | Financials | Health |
52-Week High | $90.29 | $11.19 |
52-Week Low | $56.41 | $6.22 |
Dividend Yield | 3.64% | — |
Enterprise Value | — | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
